Morgan Stanley Kintara Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.14 - $6.8 $140 - $6,840	1,006 Added 219.65%	1,464 $0
Q2 2022 Oct 27, 2022	SELL	$0.14 - $0.5 $700 - $2,500	-5,000 Reduced 91.61%	458 $0
Q2 2022 Aug 15, 2022	SELL	$0.14 - $0.5 $700 - $2,500	-5,000 Reduced 91.61%	458 $0
Q1 2022 Oct 27, 2022	BUY	$0.31 - $0.55 $1,550 - $2,750	5,000 Added 1091.7%	5,458 $2,000
Q1 2022 May 13, 2022	SELL	$0.31 - $0.55 $1,065 - $1,890	-3,437 Reduced 38.64%	5,458 $2,000
Q4 2021 Feb 14, 2022	BUY	$0.51 - $1.04 $1,625 - $3,314	3,187 Added 55.83%	8,895 $4,000
Q3 2021 Nov 15, 2021	BUY	$0.82 - $2.3 $4,680 - $13,128	5,708 New	5,708 $5,000

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.